Valneva stock ranks among the strongest gainers of the SBF 120 in trading session

A rebound of 3.29% that leaves the security below its three moving averages

The Valneva stock gains 3.29% to €2.64 in trading, among the strongest gainers of the SBF 120 which advances 0.66%. The security nonetheless remains below its 20-day moving average (€2.78, down 5.14%) and its 200-day moving average (€3.07, down 14.10%), such that this rebound does not yet change the underlying configuration. It comes after a decline of 4.8% over the week, and the price is holding near the €2.54 support level, which was breached in early October then reclaimed.

Over one month, the value loses 10.76%; over one year, the decline reaches 47%. Valneva is listed on only two exchanges: the ordinary share in Paris, eligible for the PEA, and the ADR on the Nasdaq, which represents two shares. Paris concentrates the bulk of trading, with a volume approximately twenty times higher than that of the American line.

First-half results confirm 2026 outlook despite travel headwinds

Upon publication of H1 2026 results on August 13, the group confirmed its outlook for the year, while noting that the geopolitical context continues to weigh on travel and therefore vaccine sales. Among the risks cited is notably the dependency on IXIARO deliveries to the United States Department of Defense, whose schedule remains uncertain. On the opportunities side, the company mentions regulatory decisions expected within the next twelve months for its Lyme disease vaccine candidate, as well as an improvement in gross margins in the second half.

The RSI at 39 remains in neutral territory, with no oversold signal at this stage. The support level to monitor is €2.54, near which the security is trading.